VJHemOnc is committed to improving our service to you

Share this video  

VJHemOnc is committed to improving our service to you

EHA 2020 | Assessing high-risk AML

Nigel Russell, MD, of Guy’s Hospital NHS Trust, London, UK, explores how high-risk acute myeloid leukemia (AML) can be identified as well as the importance of genomic profiling and minimal residual disease (MRD) in AML assessment. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter